Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15946361 | 0.98 | EPHX2 (0.54) | EPHX2KMT2AUSP2MDM2CASP3 | |
| SCHEMBL8239124 | 0.85 | EPHX2 (0.60) | EPHX2KMT2ANPSR1MDM4TP53 | |
| SCHEMBL15948140 | 0.85 | EPHX2 (0.57) | EPHX2KMT2ACASP3SMN1; SMN2NPC1 | |
| SCHEMBL15948141 | 0.85 | EPHX2 (0.57) | EPHX2KMT2AMDM2CASP3SMN1; SMN2 | |
| SCHEMBL15946351 | 0.84 | KMT2A (0.47) | EPHX2KMT2ACASP3RAB9A | |
| SCHEMBL30833078 | 0.84 | EPHX2 (0.62) | EPHX2KMT2ACASP3SMN1; SMN2NPC1 | |
| SCHEMBL27810168 | 0.83 | EPHX2 (0.60) | EPHX2KMT2AMDM2CASP3IDO1 | |
| SCHEMBL29561956 | 0.83 | EPHX2 (0.63) | EPHX2KMT2ACASP3MDM4TP53 | |
| SCHEMBL29401210 | 0.83 | EPHX2 (0.63) | EPHX2KMT2ACASP3MDM4TP53 | |
| SCHEMBL118052 | 0.83 | EPHX2 (0.63) | EPHX2KMT2ACASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | UWM RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | DHX15, DDX5, DHX35 | EPHX2 524/4885KMT2A 3831/4885USP2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.